MedPath

The Effects of Inositol on Glucose Metabolism in Patients with Metabolic Syndrome At Risk of Cardiac Fibrosis

Not Applicable
Recruiting
Conditions
Cardiac Fibrosis
Metabolic Syndrome
Registration Number
NCT05689710
Lead Sponsor
Lo.Li.Pharma s.r.l
Brief Summary

The study aims to evaluate the effects of an oral supplementation based on inositols and alpha-lactalbumin on principals metabolic parameters in patients with metabolic syndrome at risk of cardiac fibrosis

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Body weightFour time points: changes in body weight (kg) from the baseline to 30, 90, 180 days
Secondary Outcome Measures
NameTimeMethod
TrygliceridesFour time points: changes in blood levels of tryglycerides from the baseline to 30, 90, 180 days

Plasmatic levels of tryglicerides

HypertensionFour time points: changes in values of systolic and diastolic blood pressure from the baseline to 30, 90, 180 days

sphygmomanometer

Trial Locations

Locations (1)

UOC Medicina Interna e Nefrologia P.O. AQ

🇮🇹

L'Aquila, Italy

UOC Medicina Interna e Nefrologia P.O. AQ
🇮🇹L'Aquila, Italy
Davide Grassi, MD
Contact
333 2123716
davide.grassi@cc.univaq.it

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.